rs1136410, PARP1

N. diseases: 70
Disease: Primary malignant neoplasm ×
Source: ALL
Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.060 GeneticVariation BEFREE Few studies have reported an association between PARP1 Val762Ala polymorphism (rs1136410) and cancer therapy response. 27323894 2017
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.060 GeneticVariation BEFREE Despite some limitations, this meta-analysis found evidence for an association between the PAPR1 Val762Ala and cancer susceptibility within gastric cancer, brain tumor and Asian subgroups. 24489833 2014
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.060 GeneticVariation BEFREE The present meta-analysis provides evidence that the PARP-1 Val762Ala may be involved in cancer development at least in some ethnic groups (Asian) or some specific cancer types (gastric, cervical, and lung cancers, and glioma). 24853559 2014
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.060 GeneticVariation BEFREE Overall, no significant association was found between the PARP-1 V762A polymorphism and cancer</span> risk. 22127734 2012
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.060 GeneticVariation BEFREE Our racial and tissue-specific summary estimates imply consideration of the Val762Ala polymorphism as candidate gene marker for screening cancer patients' best suited for PARP inhibitor therapy. 23073772 2012
Primary malignant neoplasm
CUI: C1306459
Disease: Primary malignant neoplasm
0.060 GeneticVariation BEFREE Poly(ADP-ribose) polymerase activity can be higher in cancer than in adjacent normal tissue, but cancer predisposition is reported to be greater in individuals with a single-nucleotide polymorphism (SNP) V762A (T2444C) in the catalytic domain that reduces PARP-1 activity. 19568233 2009